

Appointment of Chief Financial Officer and Company Secretary

Genetic Signatures [ASX:GSS], a global molecular diagnostics company, is pleased to advise it has appointed Mr Karl Pechmann as Chief Financial and Operating Officer (CFO & COO) and Company Secretary effective 26 June 2023.

Mr Pechmann is a senior executive focused on driving organisational growth and has extensive experience in ASX-listed companies and multi-national organisations, including OncoSil Medical Limited, Kyckr Limited and Immuteq Limited. In these roles, Mr Pechmann has been responsible for numerous operational areas including finance, investor relations, treasury, operations and information technology. Mr Pechmann is a qualified Chartered Accountant and Chartered Secretary.

The appointment of Mr Pechmann follows the resignation of Mr Peter Manley on 27 March 2023, and will succeed the current Interim CFO and Company Secretary, Mr Anthony Rule.

“The Company is pleased to welcome Karl as our new CFO & COO and Company Secretary”, says Chief Executive, Dr John Melki. “His relevant financial and operational expertise in rapidly growing medical technology, biotechnology and healthcare businesses makes him the ideal candidate to lead our CFO & COO and Company Secretarial functions as we commercialise the **3base**[®] platform technology globally. On behalf of the Board, I would like to express our appreciation to Mr. Anthony Rule for his highly valuable contributions as the Interim CFO and Company Secretary over the past few months. We are truly grateful for his dedicated service during our search for a permanent replacement for these roles.”

For further information, see our website (www.geneticsignatures.com) or contact us as below:

Dr John Melki
Chief Executive Officer
john.melki@geneticsignatures.com
T: +61 (0)2 9870 7580

Karl Pechmann
Chief Financial Officer
karl.pechman@geneticsignatures.com

About Genetic Signatures Limited: Genetic Signatures is a specialist molecular diagnostics (MDx) company focused on the development and commercialisation of its proprietary platform technology, 3base[®]. Genetic Signatures designs and manufactures a suite of real-time Polymerase Chain Reaction (PCR) based products for the routine detection of infectious diseases under the *EasyScreen*[™] brand. Genetic Signatures' proprietary MDx 3base[®] platform technology provides high-volume hospital and pathology laboratories the ability to screen for a wide array of infectious pathogens, with a high degree of specificity, in a rapid throughput (time-to-result) environment. Genetic Signatures' current target markets are major hospitals and pathology laboratories undertaking infectious disease screening. Genetic Signatures is leveraging strong COVID-19 related sales of its *EasyScreen*[™] respiratory kits and the growing interest in its gastroenteritis products to further commercialise its 3base[®] technology to rapidly and cost effectively screen for a wide array of infectious pathogens including antibiotic resistant bacteria, sexually transmitted infections, meningitis and mosquito borne viral diseases.